title: Clinical axillary recurrence after sentinel node biopsy in breast cancer: a follow-up study of 220 patients.
abstract: OBJECTIVE
  The aim of this study was to evaluate the frequency of false-negative (FN) sentinel node procedures in patients with breast cancer and the subsequent clinical outcome in such patients.
  
  
  METHODS
  A total of 325 breast cancer patients underwent sentinel lymph node biopsy at our institution between June 1998 and May 2004. A 2-day protocol was used to localise the sentinel node with the injection of 99mTc-nanocolloid. There were two phases in the study: the learning phase (105 patients) and the application phase (220 patients). In the learning phase, a complete lymphadenectomy was always performed. In the application phase, sentinel nodes were studied intraoperatively and lymphadenectomy was performed when considered warranted by the pathological intraoperative results.
  
  
  RESULTS
  The median follow-up duration in the 220 patients studied during the application phase was 21.2 months (range 4-45 months). In this phase a total of 427 sentinel nodes were obtained (range 1-5 per patient, median 1.99), with 66 positive sentinel nodes in 56 patients (26%). The lymphadenectomies performed were also positive in 25% of cases (14 patients). We observed a total of two false-negative sentinel lymph node results (3.45%). One of them was found during the surgical excision of non-sentinel nodes, and the other presented as an axillary recurrence 17 months postoperatively (1.72% clinical false-negative rate). The latter patient died 1 year after the first recurrence.
  
  
  CONCLUSIONS
  After a median follow-up of 21.2 months we observed only one clinical recurrence among 220 patients. Our results indicate that adequate local control is achieved by application of the sentinel node protocol.
authors.affiliation: Department of Gynecology and Obstetrics, Breast Pathology Unit, Hospital Clinic, University of Barcelona, Spain. 30039asp@comb.es
authors.forename: A
authors.initials: A
authors.lastname: Sanjuàn
authors.forename: S
authors.initials: S
authors.lastname: Vidal-Sicart
authors.forename: G
authors.initials: G
authors.lastname: Zanón
authors.forename: J
authors.initials: J
authors.lastname: Pahisa
authors.forename: M
authors.initials: M
authors.lastname: Velasco
authors.forename: P L
authors.initials: PL
authors.lastname: Fernández
authors.forename: G
authors.initials: G
authors.lastname: Santamaría
authors.forename: B
authors.initials: B
authors.lastname: Farrús
authors.forename: M
authors.initials: M
authors.lastname: Muñoz
authors.forename: J
authors.initials: J
authors.lastname: Albanell
authors.forename: F
authors.initials: F
authors.lastname: Pons
authors.forename: J A
authors.initials: JA
authors.lastname: Vanrell
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001365:Axilla / Q000000981:diagnostic imaging / Q000473:pathology; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology*; D005188:False Negative Reactions; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000000981:diagnostic imaging* / Q000473:pathology* / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging* / Q000473:pathology*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*; D013668:Technetium Tc 99m Aggregated Albumin; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D013668:Technetium Tc 99m Aggregated Albumin; C083602:technetium Tc 99m nanocolloid